- Home
- PAYO vs APLS Comparison
PAYO vs APLS Comparison
Compare PAYO & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAYO | APLS |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.7B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | PAYO | APLS |
|---|---|---|
| Price | $5.94 | $25.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 19 |
| Target Price | $9.79 | ★ $33.11 |
| AVG Volume (30 Days) | ★ 2.6M | 2.2M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.18 | ★ 0.36 |
| Revenue | ★ $1,039,820,000.00 | $1,016,397,000.00 |
| Revenue This Year | $11.18 | $29.00 |
| Revenue Next Year | $7.45 | N/A |
| P/E Ratio | ★ $32.53 | $70.45 |
| Revenue Growth | 10.58 | ★ 42.11 |
| 52 Week Low | $4.92 | $16.10 |
| 52 Week High | $11.19 | $35.71 |
Technical Indicators
Market Signals| Indicator | PAYO | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 67.89 |
| Support Level | $5.61 | $23.54 |
| Resistance Level | $5.98 | $25.52 |
| Average True Range (ATR) | 0.16 | 0.92 |
| MACD | 0.05 | 0.61 |
| Stochastic Oscillator | 93.52 | 92.36 |
Price Performance
Historical ComparisonAbout PAYO Payoneer Global Inc.
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.